Non-invasive Ocular Biomarker Detection for Early Diabetes Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing diabetes, such as measuring blood sugar levels and glycated hemoglobin, are prone to false negatives and fluctuations, particularly in early stages, and do not effectively account for rapid protein turnover and modifications in ocular proteins like alpha-crystallin, which are critical for diagnosing diabetes-related eye diseases like cataracts and presbyopia.
Innovation Solution
A non-invasive diagnostic method using steady state and time-resolved fluorescence measurements to detect spectroscopic changes in ocular lens proteins, specifically advanced glycation end-products (AGEs), which form due to non-enzymatic glycation, allowing for early detection of diabetes and related ocular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood sugar levels are measured for diabetes diagnosis, then diagnosis can be performed, but false negative results occur due to fluctuations in blood sugar levels
Solution Approach 1:
The patent uses glycated proteins (albumin, immunoglobulins) as intermediary biomarkers that reflect long-term glucose exposure. These proteins serve as mediators between blood glucose levels and diagnostic measurement, providing a stable indicator that isn't subject to the same fluctuations as immediate blood sugar measurements.
Solution Approach 2:
The patent measures not only blood sugar levels but also glycated protein levels and glycating agent levels in ocular fluids. This partial measurement approach focuses on specific biomarkers (glycated albumin, immunoglobulins) that provide complementary information to standard blood glucose measurements, reducing false negatives.
2Reliability
If glycated hemoglobin (HbA1c) is measured for diabetes diagnosis, then long-term glucose control can be monitored, but results vary due to rapid red blood cell turnover and hemoglobin variants
Solution Approach 1:
The patent changes the measurement parameter from HbA1c (glycated hemoglobin) to glycated albumin and immunoglobulin levels in ocular fluids. This parameter change avoids the issues of rapid red blood cell turnover and hemoglobin variants while still reflecting long-term glucose exposure through glycation of long-lived proteins.
Solution Approach 2:
The patent extracts the diagnostic measurement from blood (where HbA1c issues occur) and relocates it to ocular fluids (aqueous humor, vitreous humor). This extraction allows measurement of glycated proteins in a compartment that is accessible, stable, and free from the turnover problems of circulating red blood cells.
3Loss of time
If traditional diagnostic tests are used, then diagnosis can be performed, but early stage diabetes may be missed leading to delayed treatment and permanent organ damage
Solution Approach 1:
The patent performs preliminary measurement of glycated protein levels and glycating agent levels in ocular fluids before traditional diabetes symptoms manifest. By measuring these biomarkers early, the system enables preliminary detection of diabetes risk and initiates monitoring before permanent organ damage occurs.
Solution Approach 2:
The patent replaces the mechanical/invasive system of blood draws and laboratory processing with an optical measurement system that analyzes ocular fluids. This substitution enables non-invasive, rapid measurement of glycated proteins and glycating agents, facilitating earlier and more frequent screening.
4Ease of operation
If ocular lens proteins are monitored for glycation, then non-invasive early diagnosis is possible, but the method requires sophisticated spectroscopic measurements
Solution Approach 1:
The patent develops a multi-functional diagnostic system that measures multiple biomarkers (glycated albumin, glycated immunoglobulins, glycating agents) using a single spectroscopic platform. This universal system can detect various diabetes-related ocular conditions through different molecular targets, justifying the device complexity through comprehensive diagnostic capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables accurate and early diagnosis of diabetes by identifying biomarkers in ocular tissues, preventing further complications by initiating treatment promptly and providing a reliable alternative to traditional diagnostic tests.
Implementation Method 1
detecting fluorophores that formed in the ocular cells and tissue by steady state fluorescence
Implementation Method 2
quantifying the fluorophores using time resolved fluorescence for determining the fluorescence lifetimes of the fluorophores
Data Source
AI summary
Materials and methods are disclosed for screening advanced glycation end-products from mammalian ocular lens proteins to quantify early biomarkers for the diagnosis of diseases such as diabetes mellitus and to prevent related complications.